ADC Therapeutics and Adagene have partnered up to combine ADCT's PBD Technology with Adagenes SAFEbody technology.
The advantages here are clear. PBDs have been having a rough go lately (see AbbVie's Rova-T results), and ADCT would like to see their PBDs be able to more specifically target cancer cells to get around the high toxicity of PBDs.
And if you are working for CytomX your ears should be ringing, because this is the exact type of argument that CytomX is making with their Probody technology:
Are targeting strategies like this going to be enough to make PBDs viable, or are PBDs dead? What do you think?